FDA Approval Decisions Changing In Light Of Relabeling Failures - Woodcock
• By The Pink Sheet
FDA is not approving some prescription drugs because of a lack of confidence in labeling restrictions to ensure appropriate prescribing behavior, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said during a National Public Radio interview Dec. 19.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
A new EU strategy to ensure access to essential medicines will boost the development of critical medical counter measures, including vaccines and therapies, according to one pharmaceutical industry group.
In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.
The Senate Health, Education, Labor and Pensions Committee voted to advance Monarez's nomination to lead the CDC as the agency announced the largest US measles outbreak in 22 years.